Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
|Articles|January 26, 2015
- Head and Neck Cancers (Issue 3)
- Volume 3
- Issue 1
Body Composition and Targeted Therapies in Thyroid Cancer
Author(s)Lily Kwatampora, MD
Lily Kwatampora, MD, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.
Advertisement
Lily Kwatampora, MD, a 2nd year fellow from Baylor College of Medicine at The University of Texas MD Anderson Cancer Center, discusses the relationship between body composition and targeted therapies in patients with thyroid cancer.
Articles in this issue
over 11 years ago
Perspectives From the Clinic on AE Management in Thyroid Cancerover 11 years ago
Urging Families With Thyroid Cancer to Seek Genetic Testingalmost 12 years ago
Prognosis in Thyroid Cancer as Diverse as the Diseasealmost 12 years ago
The Diagnosis of Thyroid Canceralmost 12 years ago
National Surge in Thyroid Cancer Under Scrutinyalmost 12 years ago
The Challenges of Treating Follicular Cell-Derived Thyroid Carcinomaalmost 12 years ago
Epidemic in Sex-Related Oral Cancer Highlights Need for GuidelinesAdvertisement
Related to this article
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5